Home » Case Studies Catalog » ESG Pharmaceutical Resilience
Author : Azzeddine Allioui
Synopsis
In 1976, Sothema, a visionary family-owned pharmaceutical company in Morocco, embarked on a journey that would redefine the pharmaceutical landscape in the country. Founded by the Tazi family, the company initially started with a single production facility. Over the next several decades, Sothema expanded its network of facilities, demonstrating a commitment to providing accessible, high-quality pharmaceutical products across Morocco. By 2020, Sothema had already established itself as a significant player in the pharmaceutical sector with multiple production sites and a diverse product portfolio. However, the onset of the COVID-19 pandemic presented an unprecedented challenge. The crisis not only tested the resilience of Sothema’s infrastructure but also the strategic acumen of its leadership. By examining the company’s strategic decisions and performance, you will identify key factors contributing 2 to Sothema’s resilience and provide recommendations for future growth and stability in the ever-evolving pharmaceutical landscape.
Key Concepts / Keywords
strategic expansion, ESG integration, crisis management, leadership, sustainable leadership, corporate governance, Pharmaceutical industry.
Learning Objectives
Target Learning Groups
The case study is designed to cater to a diverse audience, ranging from master’s degree students specializing in financial management and corporate strategy to executives and managers in the pharmaceutical sector.
Prerequisites
Have basic knowledge of financial analysis and diagnosis.
▪ Master the tools of strategic diagnosis (SWOT, PORTER).
▪ Have basic knowledge of corporate strategy.
▪ Mastering strategic management.
▪ Mastering corporate finance.
Case Caracteristics
67-3 Avenue de l’Aéropostale Casablanca Finance City (CFC) 20250 Casablanca – Maroc
Tél :+212(0) 522 20 91 20
Fax :+212(0) 522 20 91 15